EVERJOY HEALTH(SZ:002162)2025-10-24 08:00Financial Performance - The company's operating revenue for Q3 2025 was ¥283,318,009.11, a decrease of 14.24% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2025 was ¥1,294,779.88, an increase of 103.65% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,284,174.91, a decrease of 96.81% compared to the same period last year[5]. - The basic earnings per share for Q3 2025 was ¥0.0014, up 103.63% year-on-year[5]. - Total operating revenue decreased to ¥771,308,298.16 from ¥888,897,808.68, a decline of approximately 13.2% year-over-year[22]. - Total operating costs decreased to ¥772,782,653.64 from ¥912,768,563.09, a reduction of about 15.4% year-over-year[23]. - Net profit for the period was ¥1,936,682.35, compared to a net loss of ¥35,761,583.82 in the previous period, marking a significant turnaround[24]. - Operating profit improved to ¥3,735,902.32 from a loss of ¥31,000,906.45, indicating a recovery in operational performance[23]. - The company reported a basic earnings per share of ¥0.0034, recovering from a loss of ¥0.0358 per share in the previous period[24]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥32,096,895.16, a decrease of 4.24% compared to the previous year[5]. - Cash flow from operating activities generated a net cash inflow of ¥32,096,895.16, slightly down from ¥33,518,001.83 in the previous period[25]. - Cash inflow from investment activities totaled $42,788,896.31, while cash outflow amounted to $69,100,657.85, resulting in a net cash flow of -$26,311,761.54[26]. - Cash inflow from financing activities was $359,142,227.13, with cash outflow of $320,459,960.00, leading to a net cash flow of $38,682,267.13[26]. - The net increase in cash and cash equivalents for the period was $44,467,406.32, compared to a decrease of $48,281,116.25 in the previous period[26]. - The ending balance of cash and cash equivalents was $190,113,027.75, up from $145,645,621.43 at the beginning of the period[26]. - The company received $302,655,000.00 in cash from borrowings during the financing activities[26]. Assets and Liabilities - Total assets at the end of Q3 2025 were ¥2,005,799,476.26, a decrease of 2.53% from the end of the previous year[5]. - The total assets as of September 30, 2025, amounted to 2,005,799,476.26, a decrease from 2,057,924,527.48 at the beginning of the period[19]. - Current assets totaled 670,307,389.01, slightly up from 650,211,849.95 at the beginning of the period[19]. - The total liabilities decreased to ¥1,169,501,554.59 from ¥1,214,146,314.58, reflecting a reduction in financial obligations[22]. - Total equity decreased to ¥836,297,921.67 from ¥843,778,212.90, indicating a slight decline in shareholder value[22]. - The company reported a total of 1,335,492,087.25 in non-current assets, down from 1,407,712,677.53 at the beginning of the period[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 53,403, with no preferred shareholders having restored voting rights[14]. - CIMIC INDUSTRIAL INC. holds the largest share at 37.43%, with 344,206,164 shares pledged amounting to 200,000,000[14]. Investment and Expenses - The company reported a significant increase in investment income of ¥6,143,469.49, a rise of 256.29% year-on-year, mainly due to increased debt restructuring gains[10]. - The company experienced a 165.58% increase in credit impairment losses, reflecting a shift in credit policy that reduced credit risk[12]. - Research and development expenses were ¥4,952,013.58, down from ¥5,860,659.43, suggesting a potential shift in investment strategy[23]. - The company received ¥68,831,569.65 in cash related to other operating activities, down from ¥113,643,475.00, indicating a decrease in operational cash inflows[25]. Other Information - The third quarter financial report was not audited[27].